| Autor: |
Sepúlveda-Hermosilla, Gonzalo, Freire, Matías, Blanco, Alejandro, Cáceres, Javier, Lizana, Rodrigo, Ramos, Liliana, Assar Cuevas, Rodrigo, Ampuero, Diego, Aren, Osvaldo, Chernilo, Sara, Spencer, María L., Bernal, Giuliano, Flores, Jacqueline, Rasse, Germán, Sánchez, Carolina, Marcelain, Katherine, Rivas, Solange, Branco, Gabriela P., Galli de Amorim, María, Nunes, Diana N., Dias-Neto, Emmanuel, Freitas, Helano C., Fernández, Cristina, Araujo, Luiz, Pires, Luis, Skare, Nils, Girotto, Gustavo, Zereu, Manuela, Freitas, Helano, Tadokoro, Hakaru, Gelatti, Ana Caroline, Moura, Jose Fernando, Mathias, Clarissa, De Marchi, Pedro Rafael, Silva, Fernando, de Santos, Mayler Olombrada Nunes, Dracoulakis, Marianna Deway Andrade, Costa, Renata Pinho, Castro, Luciana, de Oliveira Salles, Paulo Guilherme, Campos, Clodoaldo Zago, Livia, Maria Andrade, Chernilo, Sara, Arén Frontera, Osvaldo, Yanez Ruiz, Eduardo, Olea, Monica Ahumada, Bernal, Giuliano, Spencer, Loreto, Vasquez, Alejandro Ortega, Rasse, German, Bertoglio, Juan, Silvera, Jose David Zorrilla, Escobar, Hernan Moron, Gonzalez, Luis Riva, Lopez, Luis Alberto Mas, De Mendoza Acurio, José Luis Fernando Hurtado, Abrill Mendoza, Giovanna Victoria, Aguilar, Alfredo, Siccha, Gerardo Campos, Sevillano, Ricardo Sanchez, Fernández, Cristina, Chandía, Sylvia, Araos, Pablo, Mejías, Ana, Angulo, Francisca, Sánchez, Carolina, Troncoso, Jessica, Jara, David, Astete, Marcela, Galleguillos, María Jesús, Dias-Neto, Emmanuel, Freitas, Helano Carioca, de Amorim, María Galli, Nunes, Diana Noronha, Branco, Gabriela, Eloi, Marina, Pizzi, Melissa, Silva, Jordana, Bartelli, Thais F., Marcelain, Katherine, Toro, Jessica, Oliveira-Cruz, Luciana, Diez, Daniela, Rivas, Solange, Pérez, Paola, Armisén, Ricardo |
| Zdroj: |
The Journal of Molecular Diagnostics; September 2021, Vol. 23 Issue: 9 p1127-1137, 11p |
| Abstrakt: |
About 4% to 7% of the non–small-cell lung cancer patients have anaplastic lymphoma kinase (ALK) rearrangements, and specific targeted therapies improve patients' outcomes significantly. ALKgene fusions are detected by immunohistochemistry or fluorescent in situhybridization as gold standards in South America. Next-generation sequencing–based assays are a reliable alternative, able to perform simultaneous detection of multiple events from a single sample. We analyzed 4240 non–small-cell lung cancer samples collected in 37 hospitals from Chile, Brazil, and Peru, where ALK rearrangements were determined as part of their standard of care (SofC) using either immunohistochemistry or fluorescent in situhybridization. A subset of 1450 samples was sequenced with the Oncomine Focus Assay (OFA), and the concordance with the SofC tests was measured. An orthogonal analysis was performed using a real-time quantitative PCR echinoderm microtubule-associated protein-like 4-ALK fusion detection kit. ALK fusion prevalence is similar for Chile (3.67%; N = 2142), Brazil (4.05%; N= 1013), and Peru (4.59%; N= 675). Although a comparison between OFA and SofC assays showed similar sensitivity, OFA had significantly higher specificity and higher positive predictive value, which opens new opportunities for a more specific determination of ALKgene rearrangements. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
